AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic rosuvastatin dose based on CPIC guidelines
Description: Rosuvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic pravastatin dose based on CPIC guidelines
Description: Pravastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic lovastatin dose based on CPIC guidelines
Description: Lovastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preemptive pharmacogenetic fluvastatin dose based on CPIC guidelines
Description: Fluvastatin at the dosage reccomended by the 2022 Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and considerations for Statin-Associated Musculoskeletal Symptoms based on the subjects pharmacogenetic phenotype. A comprehensive description of said doses are can be accessed at: https://cpicpgx.org/guidelines/cpic-guideline-for-statins/
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of atorvastatin
Description: Subject allocated to this arm will receive the atorvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of simvastatin
Description: Subject allocated to this arm will receive the simvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of pitavastatin
Description: Subject allocated to this arm will receive the pitavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of rosuvastatin
Description: Subject allocated to this arm will receive the rosuvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of prasavastatin
Description: Subject allocated to this arm will receive the prasavastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of lovastatin
Description: Subject allocated to this arm will receive the lovastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
Study NCT06262685 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SoC) dosing of fluvastatin
Description: Subject allocated to this arm will receive the fluvastatin according to clinical practice and the drug's product labelling, and never exceeding the already authorized dosages. These subject will not receive a personalised dosed/prescription based on their pharmacogenetic phenotype.
Study NCT05941767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine nebulization
Description: The patient will receive nebulized dexmedetomidine via face mask nebulizer 10 minutes before induction of general anesthesia.
Study NCT05941767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine nebulization
Description: The patient will receive nebulized lidocaine 4% (3 mg /kg) 10 minutes before induction of general anesthesia.
Study NCT05941767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine IV
Description: The patient will receive intravenous infusion via a syringe pump of dexmedetomidine (1 ml= 4mcg) started at a dose of 1 mcg/kg 20 minutes before induction of general anesthesia.
Study NCT05941767 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: The patient will receive 1.5 mg/kg lidocaine 2% (1 ml = 20mg) completed to 10 ml with normal saline 0.9% intravenous 90 seconds before induction of general anesthesia.
Study NCT04734691 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PIPAC
Description: PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
Study NCT04734691 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PIPAC
Description: PIPAC is a laparoscopic procedure for intraperitoneal administration of chemotherapy
Study NCT04634825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Anti-B7-H3 antibody
Study NCT04634825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Anti-PD-1 antibody
Study NCT04634825 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tebotelimab
Description: PD-1 X LAG-3 bispecific DART molecule
Study NCT06215430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Tablet
Description: Administered orally.
Study NCT06215430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole capsule
Description: Administered orally.
Study NCT06215430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin tablet
Description: Administered orally.
Study NCT06215430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-305
Description: Administered orally.
Study NCT06144177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dark with star projector
Description: When in the operating room prior to the start of induction, the room will be darkened, and a star projector that lights up the ceiling and walls will be turned on.
Study NCT06144177 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative midazolam
Description: Midazolam by mouth preoperatively.
Study NCT06144177 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parental Presence
Description: A parent or guardian will accompany the child into the OR and be present for the start of induction.
Study NCT05766813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenrispodun
Description: Lenrispodun 30 mg tablets administered orally, once daily.
Study NCT05766813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching tablets administered orally, once daily.
Study NCT02703597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: Surveys include questions related to tobacco use behavior and attitude toward tobacco, as well as demographic and personality questions. Psychosocial surveys and social network surveys are also completed to capture adolescents' network of friends and opinion leaders.
Study NCT02703597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASPIRE
Description: Participants engage in four to five 70-minute sessions of ASPIRE spread over a period of 4 weeks. During ASPIRE use, participants face a screen and individually watch videos and engage in computer-based activities related to the negative effects of tobacco.
Study NCT02703597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GSA-ASPIRE-Network
Description: In groups, participants engage in four to five 70-minute sessions of ASPIRE conducted over a period of 4 weeks. However, during each session, ASPIRE use is coupled with game-based social activities (GSAs). During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, in groups, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSAs contain games about the effects of tobacco. Groups are allocated based on adolescents' network of friendships.
Study NCT03629977 — intervention group
Intervention type: DEVICE
Intervention: CRRT
Description: Continuous Renal Replacement Therapy
Study NCT06389422 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Moderate-dose Hypofractionated Intensity-modulated Radiotherapy
Description: All lesions receive moderate-dose hypofractionated intensity-modulated radiotherapy, with a gross tumor dose of 25Gy/5f, and a maximum dose of 35Gy/5f at the tumor center.
Study NCT06389422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: One week before or during the radiotherapy, patients receive concurrent Pembrolizumab at a dose of 200mg. Subsequently, Pembrolizumab is administered intravenously every 3 weeks. Follow-up examinations are conducted 1-3 months post-radiotherapy. Lenvatinib 4mg may be used for maintenance therapy with Pembrolizumab if there are no contraindications. Maintenance therapy is continued until disease progression or intolerance.
Study NCT04220463 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypnosis + NIV
Description: For the hypnosis group, hypnotic support is set up by a doctor/IDE previously trained and dedicated during the implementation of the NIV. The dedicated doctor/IDE will be presented before the start of the NIV setup procedure and will start the hypnosis session a few minutes before the mask is put on. The procedure for setting up the NAV may begin after agreement from the dedicated doctor/IDE.
Study NCT04220463 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NIV
Description: In the control group, in order to preserve the knowledge of the evaluator, the doctor/IDE dedicated to hypnosis is present in the service but does not intervene in the care so as not to be tempted to involuntarily put hypnosis in place. The assessor will be chosen from the two other teams present in the other two modules (each module is a seven-bed unit and has no physical communication with the other two) after the start of the procedure for setting up the NIV, with or without hypnosis, in order to be certain that he had no visual contact with the patient and the caregivers present before the evaluation. The implementation of the NAV will take place as usually carried out in the service.
Study NCT04984733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Metronomic TMZ 50mg/m2/day orally for 3 months then nivolumab 240mg IV +/- TMZ until progression.~Patients who don't progress on TMZ will commence with combination treatment; TMZ + Nivolumab at 3 mths. Patients who progress on TMZ will start monotherapy with nivolumab. Patients will remain on monotherapy with nivolumab or combination therapy until progression or up to a maximum of 24mths.
Study NCT04984733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 50mg/m2/day
Description: Metronomic TMZ 50mg/m2/day orally until progression then nivolumab 240mg IV until progression
Study NCT04984733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 3 month
Description: Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until progression.
Study NCT04984733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide 24month
Description: Metronomic TMZ 50mg/m2/day orally for 3 months, then nivolumab 240mg IV and TMZ until a maximum of 24 months
Study NCT05208866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixivaptan
Description: Oral vasopressin V2 receptor antagonist
Study NCT05864261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JT1801 60ug
Description: JT1801, 60ug, IV injection
Study NCT06087653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Low-dose lenalidomide continuous SC infusion (STAR-LDD) in combination with bortezomib and dexamethasone
Study NCT06070883 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Amniotic membrane transplantation
Description: Amniotic membrane (AM) is the innermost layer of the placenta, which consists of a single layer of meta-bolically active epithelium, a thick basement membrane, and an avascular stromal matrix. It has been shown to exhibit a wide array of biological properties, including wound healing, anti-inflammatory, antimicrobial, and anti-angiogenic properties, amongst others. Amniotic membrane transplantation will be performed in eye OT under aseptic conditions. The necrotic tissues at the base of the ulcer will be debrided and sent for culture and sensitivity. The rolledup edge of the ulcer or the loosely adhered epithelium adjacent to the ulcer will also be removed. The amniotic membrane will be trimmed to fit the shape of the ulcer and placed with its epithelial side up. Then the amniotic membrane will be secured with 10-0 nylon suture (5 cases with interrupted and 25 cases with continuous suture) with the suture knots buried.
Study NCT06266247 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Take blood samples
Description: Tnf alpha, sirtuin and il-6 levels will be examined in patients with Behcet\&amp;#39;s disease using biological drugs and not using biological drugs
Study NCT05468996 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: A loading dose of remimazolam is 1mg/kg/hr. When sedation is achieved, the dose of remimazolam is adjusted to the assigned dose. The maintenance dose of remimazolam begins at 1.0mg/kg/hr. When the maintenance is not successful during the surgery, the maintenance dose will be increased by 0.1-0.2mg/kg/hr in the next patient. When the maintenance is successful, the dose will be decreased by 0.1-0.2mg/kg/hr. (maximal dose: 2mg/kg/hr)
Study NCT05864261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP 60ug
Description: NESP, 60ug, IV injection
Study NCT05710861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F-HIFU
Description: A F-HIFU treatment will be performed with the Focal-One® machine according to the predefined treatment area for each patient using the standard procedure in place in each therapeutic center and according to the user's manual edited by the company, under locoregional or general anaesthesia.
Study NCT05710861 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: A Radical Prostatectomy will be performed according to the standard procedure in place in each center, under general anaesthesia, through an open, laparoscopic or robot-assisted laparoscopic approach
Study NCT05402748 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placenta-MSCs derived exosomes
Description: Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
Study NCT05402748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placenta-MSCs derived exosomes
Description: Exosomes are extracellular vesicles that are 30 to 150 nm in diameter. these vesicles are secreted from various cells. Mesenchymal stem cells exhibit immunomodulatory and anti- inflammatory properties by the use of paracrine effects. Exosomes as a vehicle for signaling, are responsible for a major part of cell to cell signaling. The preclinical animal studies manifested high safety and efficacy for MSC derived exosome treatment on various fistulas and inflammatory bowel disease. In this study we aimed to evaluate the safety and efficacy of Placenta-MSCs derived exosomes in treatment of patients with complex preanal fistula (non-crohn's) in phase I and II of clinical trial.
Study NCT05373589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional ventilation, group C
Description: In the conventional ventilation group, after stopping the administration of the inhalation gas, the emergence process is performed by the anesthesiologist assigned to the room. Basically, until spontaneous respiration of the patient is restored, an anesthesiologist can assist respiration by intermittent manual assistance if necessary.
Study NCT05373589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pressure support, group PS
Description: In the pressure support group, after stopping the administration of the inhalation gas, switch to the pressure support mode at the emergence period. PEEP 5cmH20 is applied, and the safety backup ventilation rate is set to 12 breaths/min. The flow trigger is set to 1L/min, and the degree of support is made to be 7-8ml of the predicted body weight, and is decreased as the patient's spontaneous breathing is restored.
Study NCT05065333 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Septic Shock Clinical Decision Support
Description: The intervention will be activating a septic shock clinical decision support tool (CDS) in the Electronic Health Record at the site, making it available to trigger and alert Emergency Department providers during clinical care. Patients will be identified when providers suspect sepsis and initiate a sepsis evaluation, using the institutional, clinically-standard, sepsis pathway/orderset. After the CDS is triggered, it will use available Electronic Health Record data to calculate the risk of septic shock, using previously-published predictive models \[Ref 1, 2\]. The CDS will notify providers if the patient is at elevated risk of septic shock and prompt them to follow institutional standard care for septic shock (including close monitoring, complete laboratory evaluation for organ dysfunction, and immediate clinical involvement of an attending Pediatric Emergency Physician). All clinical care decisions will be determined by the providers.
Study NCT05065333 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Diagnosis Only
Description: Emergency Department sites in this arm will not have Clinical Decision Support for septic shock visible in the Electronic Health Record for providers at the site. Providers will follow usual institutional standards of sepsis care.
Study NCT04908462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL01211 or Placebo (Part A)
Description: Five dose groups with doses ranging from 2mg to 60 mg
Study NCT04908462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL01211 or Placebo (Part B)
Description: Five dose groups with doses ranging from 2-60 mg daily. Each separate dose given for 14 days
Study NCT06266715 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATP Group
Description: Cap escitalopram 10mg OD for four weeks and injection ATP 100mg in 100ml NS BD for two weeks.
Study NCT06266715 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Cap escitalopram 10mg OD for four weeks and injection110ml NS BD for two weeks.
Study NCT05207488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructooligosaccharides (FOS)
Description: FOS (NUTRAFLORA® P-95, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
Study NCT05207488 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Exercise
Description: During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).
Study NCT05207488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During the intervention period, all participants will perform 6 weeks of supervised progressive multi-component exercise training consisting of moderate to vigorous aerobic and strength-based exercises (3x/wk.).
Study NCT05207488 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (Globe 18DE Maltodextrin, Ingredion) supplements (10g/day) will be consumed daily mixed with water.
Study NCT05907863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Use of intracardiac echocardiography
Description: intracardiac echocardiography guided slow pathway ablation in patients with AVNRT